CareDx, Inc. · NASDAQ:CDNA
CareDx — Investor Presentation (February 2021)
24 slides from CareDx's investor presentation, February 2021
Slide 1: The Allo-Transplantation Company
The Allo-Transplantation Company Focused on better outcomes through personalized transplant surveillance February 2021 Allo-transplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues or organs to a recipient from a genetically non-identical donor of the same species
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the future financial position of CareDx, Inc. (together with its subsid
Slide 3: Our Vision and Mission
Our Vision The leading partner for the transplant ecosystem Our Mission We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey
Slide 4: Q4 2020 Highlights
Q4 2020 Highlights Operational Financial > 6,000 RemoTraC Patients > $200M Annual Revenue Run Rate > 55 AlloSure Named Protocol Centers > 64% Q4 2020 YoY Revenue Growth Final AlloSure Heart LCD 70% Non-GAAP Gross Margin* Published AlloSure Pediatrics Data 8% Adjusted EBITDA Margin* *Non-GAAP measure
Slide 5: Platform in Transplantation with Growth Accelerators in Place
Platform in Transplantation with Growth Accelerators in Place Industry Strong Robust Strong Leading Medical Leading Clinical End-stage Financial Reimbursement Products & Services Data Pipeline Position Expanding $12B+ market opportunity 5
Slide 6: Multiple Touchpoints Along Patient Journey
Example: Kidney patient Multiple Touchpoints Along Patient Journey Pre-Transplant Post-Transplant Surveillance KidneyCare: Multi-modality Waitlist High Resolution “Liquid Biopsy” “AI” Gene Expression Urinary Management HLA matching dd-cfDNA Risk Prediction Profiling mRNA Electronic Medical Records >
Slide 7: CareDx's Growth Story
CareDx’s Growth Story Platform Multi-Product Single Product All Transplant Solid Organ Transplant • Services, Products & Digital • Surveillance schedule • Global Medical Institutions • Multi-modality Testing • Ecosystem Partnerships Heart Transplant • Patient Engagement • US Transplant Centers • Gen
Slide 8: Leveraging Business Development to Establish Leadership in Transplantation
Leveraging Business Development to Establish Leadership in Transplantation Acquisitions First Pre-transplant First HLA target Entry into dd-cfDNA HLA testing & capture digital technology in international sequencing transplant transplant expansion technology tools 2014 2015 2016 2017 2018 2019 2020 2
Slide 9: CareDx is the Leading Partner Across US Transplant Centers
CareDx is the Leading Partner Across US Transplant Centers KIDNEY HEART OTHER ORGANS Deep Center 70%+ 90%+ 20+ Centers Using AlloSure Centers Using AlloMap Centers Using AlloSure Lung Penetration Clinical 70+ 60+ 20+ Partnerships KOAR/OKRA Centers SHORE Centers Investigator Initiated Trials Leadersh
Slide 10: Adapting to COVID-19 World
Adapting to COVID-19 World Home Based Blood Draws for Full Blood Workup/Surveillance Transplant Patient Patient Care Mobile Field Lab Centers Consent Manager Network Support Broad Rapid Accelerated Created national Established customer interest uptake structure phlebotomy excellence group > 150 > 6K
Slide 11: Building a MOAT Around Each Center
Building a MOAT Around Each Center “We are 100% Transplant Focused. Always. ” Transplant Medical Community Account Science 1 SOLID ORGAN 4 Nephrology Team Manager (TAM) Liaison (MSL) TRANSPLANT CENTERS EMR Solutions RemoTraC 2 5 Phlebotomy Transplant Patient Care Field Lab TRANSPLANT 3 ECO-SYSTEM 6
Slide 12: Latest Innovation Transplant Care: Multi-Modality Surveillance
Latest Innovation Transplant Care: Multi-Modality Surveillance Latest Innovation 2020 Additions Gene Expression/Urine • Developed by Cornell • Gene expression for acute cellular rejection Donor-derived Cell-free DNA Machine learning Gene Expression (dd-cfDNA) Transplant Data Analytics Profiling (GEP
Slide 13: Strategic Investments in Clinical Development
Strategic Investments in Clinical Development Start Name Impact Centers Patients Samples 2020 c19txr Long-term COVID Transplant Outcomes >30 >2,000* N/A Large 2019 OKRA Long-term Kidney Transplant Outcomes >50 >1,500 >8,000 Multi-Center 2018 SHORE Long-term Heart Transplant Outcomes >50 >3,200 >8,00
Slide 14: Digital Offerings: Transplant EMR & Patient App
Digital Offerings: Provider Solutions Patient Solutions Transplant EMR & Patient App Support EMR integration and testing AITraC XynCare protocol adherence Clinical Decision Support Waitlist Management Transplant dedicated EMR based on Ottr 3.x AlloCare Electronic Medical Records Patient Engagement A
Slide 15: New: Surveillance for Engineered and Non-Engineered Allogeneic Cell Therapy
New: Surveillance for Engineered and Non-Engineered Allogeneic Cell Therapy Cell Therapy C max Cell Therapy Patient Monitoring Addressable market % Cell Product Contraction Persistence Expansion $5.5B+ Infusion Months/Years • Monitors pharmacokinetics and • Measures the amount of cell • > 300,000 pa
Slide 16: Record Growth in FY 2020
Record Growth in FY 2020 Testing Services Patient Results Total Revenue (FYE-December; in Thousands) (FYE-December; in Millions) +61% +51% 79 $192 49 $127 28 $77 16 $41 $48 14 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 16
Slide 17: Continued Momentum in Q4 2020
Continued Momentum in Q4 2020 Q4 Performance (Patient Results in Thousands; Revenue in Millions) 2019 2019 2020 2020 +64% +78% +73% $58.6 2525.1 $50.3 $35.8 14 $29.1 +17% +44% $5.1 $5.9 $1.6 $2.4 Testing Services Testing Services Products Digital & Other Total Patient Results 17
Slide 18: Significant Margin Improvement Since AlloSure Launch
Significant Margin Improvement Since AlloSure Launch Non-GAAP Gross Margin* Adjusted EBITDA Margin* (% of Revenue) (% of Revenue) +10% 71% 71% +8% 68% 68% 70% 61% +3% 60% +1% -4% -7% -24% FY 2017 FY 2018 FY 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2017 FY 2018 FY 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020
Slide 19: Pathway to Future Gross Margin Improvement
Pathway to Future Gross Margin Improvement Non-GAAP Gross Margin* (% of Revenue) Multi-modality Private Payer Reimbursement Reimbursement Lab Automation RemoTraC Testing RemoTrac Testing Volume COVID Third Wave Volume 75%+ 71% 71% 70% 68% Q1 2020 Q2 2020 Q3 2020 Q4 2020 Target *Non-GAAP measures sho
Slide 20: Upcoming Growth Drivers Across Segments
Upcoming Growth Drivers Across Segments Testing Services Transplant Products Digital Business • Patient Penetration • Global Launches • Support Testing Services • Community Nephrology • Start VA Roll-out • Pharma Partnerships • Launch Patient Engagement/App 20
Slide 21: CareDx: Your Partner in Transplant Care
é Care Dx: Your Partner in Transplant Care a é CareDx:
Slide 22: Appendix
Appendix 22 éCareDx
Slide 23: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin in Millions (except %) FY 2018 FY 2019 FY 2020 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Revenue 76.6 127.1 192.2 38.4 41.8 53.4 58.6 GAAP Cost of Revenue 33.0 45.5 63.1 12.4 15.0 16.8 18.9 Stock-based compensation expense (0.8) (2.2) (2.3) (0.4) (0.7) (0.7) (0.6) Acqui
Slide 24: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA in Millions FY 2018 FY 2019 FY 2020 Q1 2020 Q2 2020 Q3 2020 Q4 2020 GAAP Net Loss (46.8) (22.0) (18.7) (5.8) (6.6) (2.8) (3.5) Stock-based compensation expense 7.1 22.4 23.4 4.3 6.4 6.7 6.0 Acquisition related amortization of purchased intangibles 3.0 3.6 4.8 1.1 1.